Edge activators and a polycationic polymer enhance the formulation of porous voriconazole nanoagglomerate for the use as a dry powder inhaler

References

• Abdelrahim ME. (2010). Emitted dose and lung deposition of inhaled terbutaline from Turbuhaler at different conditions. Respir Med 104:682–9
   PubMed Web of Science ®Google Scholar
• Andriole VT. (1999). Current and future antifungal therapy: new targets for antifungal agents. J Antimicrob Chemother 44:151–62
   PubMed Web of Science ®Google Scholar
• Bailey MM, Gorman EM, Munson EJ, Berkland C. (2008). Pure insulin nanoparticle agglomerates for pulmonary delivery. Langmuir 24:13614–20
   PubMed Web of Science ®Google Scholar
• Bajdik J, Pintye‐Hódi K, Planinšek O, et al. (2004). Surface treatment of indomethacin agglomerates with Eudragit. Drug Dev Ind Pharm 30:381–8
   PubMed Web of Science ®Google Scholar
• Beinborn NA, Du J, Wiederhold NP, et al. (2012). Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice. Eur J Pharm Biopharm 81:600–8
   PubMed Web of Science ®Google Scholar
• Bhavane R, Karathanasis E, Annapragada AV. (2007). Triggered release of ciprofloxacin from nanostructured agglomerated vesicles. Int J Nanomed 2:407
   PubMed Web of Science ®Google Scholar
• British Pharmacopoeia (2005). Preparations for inhalation. Aerodynamic assessment of fine particles–fine particle dose and particle size distribution (Ph.Eur.method2.9.18). In: Stationery office. ed. London: British Pharmacopoeia
   Google Scholar
• De Chasteigner S, Fessi H, Devissaguet JP, Puisieux F. (1996). Comparative study of the association of itraconazole with colloidal drug carriers. Drug Dev Res 38:125–33
   Web of Science ®Google Scholar
• Dickinson RP, Richardson K. (1992). Triazole antifungal agents. Google Patents.
   Google Scholar
• Duret C, Wauthoz N, Sebti T, et al. (2012). New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis. Int J Nanomed 7:5475
   PubMed Web of Science ®Google Scholar
• Edwards DA, Ben-Jebria A, Langer R. (1998). Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 85:379–85
   PubMed Web of Science ®Google Scholar
• European Pharmacopeia (2002). 2.9.18.: Preparations for inhalation: aerodynamic assessment of fine particles. Strasbourg, France: Council of Europe
   Google Scholar
• Freitas C, Müller RH. (1998). Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions. Int J Pharm 168:221–9
   Web of Science ®Google Scholar
• Fults KA, Miller IF, Hickey AJ. (1997). Effect of particle morphology on emitted dose of fatty acid-treated disodium cromoglycate powder aerosols. Pharm Dev Technol 2:67–79
   PubMedGoogle Scholar
• Gangurde H, Chordiya M, Baste NTS, Upasani C. (2012). Approaches and devices used in pulmonary drug delivery system: a review. Asian J Pharm Res Health Care 4:11–27.
   Google Scholar
• Geller DE, Weers J, Heuerding S. (2011). Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology. J Aerosol Med Pulm Drug Deliv 24:175–82
   PubMed Web of Science ®Google Scholar
• Hancock BC, Parks M. (2000). What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17:397–404
   PubMed Web of Science ®Google Scholar
• Heyder J, Gebhart J, Rudolf G, et al. (1986). Deposition of particles in the human respiratory tract in the size range 0.005–15 μm. J Aerosol Sci 17:811–25
   Web of Science ®Google Scholar
• Jacob L, Kr A. (2013). A review on surfactants as edge activators in ultradeformable vesicles for enhanced skin delivery. Int J Pharm Bio Sci 4:337
   Google Scholar
• Jain KK. (2012). The handbook of nanomedicine. New York: Springer Science & Business Media
   Google Scholar
• Kaparissides C, Alexandridou S, Kotti K, Chaitidou S. (2006). Recent advances in novel drug delivery systems. J Nanotechnol Online 2:1–11
   Google Scholar
• Kumon M, Machida S, Suzuki M, et al. (2008). Application and mechanism of inhalation profile improvement of DPI formulations by mechanofusion with magnesium stearate. Chem Chem Pharm Bull 56:617–25
   PubMed Web of Science ®Google Scholar
• Lee SL, Adams WP, Li BV, et al. (2009). In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases. AAPS J 11:414–23
   PubMed Web of Science ®Google Scholar
• Lu Z, Liu C, Thompson J, Porter W. (2004). Structural amorphous steels. Phys Rev Lett 92:245503
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge E, Mcgurk SL, Liversidge GG. (2004). Insulin nanoparticles: a novel formulation approach for poorly water soluble Zn-insulin. Pharm Res 21:1545–53
   PubMed Web of Science ®Google Scholar
• Molimard M, Raherison C, Lignot S, et al. (2003). Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 16:249–54
   PubMedGoogle Scholar
• Papadakis SE, Bahu RE. (1992). The sticky issues of drying. Drying Technol 10:817–37
   Web of Science ®Google Scholar
• Pistel K, Kissel T. (2000). Effects of salt addition on the microencapsulation of proteins using W/O/W double emulsion technique. J Microencapsul 17:467–83
   PubMed Web of Science ®Google Scholar
• Plumley C, Gorman EM, El-Gendy N, et al. (2009). Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int J Pharm 369:136–43
   PubMed Web of Science ®Google Scholar
• Rawat A, Majumder QH, Ahsan F. (2008). Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation. J Control Release 128:224–32
   PubMed Web of Science ®Google Scholar
• Reddy YD, Sravani A, Ravisankar V, et al. (2015). Transferosomes a novel vesicular carrier for transdermal drug delivery system. J Innov Pharm Biol Sci 2:193–208
   Google Scholar
• Riddick T. (1968). Control of colloid stability through zeta potential: with a closing chapter on its relationship to cardiovascular disease, Zeta-Meter. Wynnewood (PA): Livingston Pub Co
   Google Scholar
• Salem HF, Abdelrahim M, Sharaf M. (2011). Nanosized rods agglomerates as a new approach for formulation of a dry powder inhaler. Int J Nanomed 6:311–20
   PubMed Web of Science ®Google Scholar
• Smith IJ, Parry-Billings M. (2003). The inhalers of the future? A review of dry powder devices on the market today. Pulm Pharmacol Ther 16:79–95
   PubMed Web of Science ®Google Scholar
• Thangabalan B, Salomi M, Sunitha N, Babu SM. (2013). Development of validated RP-HPLC method for the estimation of Itraconazole in pure and pharmaceutical dosage form. Asian J Pharm Anal 3:119–23
   Google Scholar
• United States Pharmacopeia. (2005). Aerosols, nasal sprays, metered dose inhalers and dry powder inhalers. The United States pharmacopeia 28 [and] The national formulary 23: The board of trustees
   Google Scholar
• Vanbever R, Mintzes JD, Wang J, et al. (1999). Formulation and physical characterization of large porous particles for inhalation. Pharm Res 16:1735–42
   PubMed Web of Science ®Google Scholar